These findings indicate that ARID2 KO TFE3-RCC cells are highly dependent on ERBB3 signaling, providing crucial experimental support for the potential use of targeted therapy in ARID2-deficient TFE3-RCC patients. The gene discussed is ERBB3; the disease is renal cell carcinoma.